

Supplementary Table 1. Main patient characteristics, univariate p-values (log-rank test) for disease-free survival (DFS) and overall survival (OS) and the mean \pm standard deviation (SD) of NANI expression for each clinical characteristic compared by T-test or ANOVA test according TNM 8th edition.


Characteristics	Value	N=86 (%)	DFS p-value	OS p-value	NANI p-value
Sex	Male	73 (74.5)	0.005	0.022	0.102
	Female	25 (25.5)			
Age, yrs	Mean (Range)	67 (38-84)	0.697	0.361	0.118
	\leq 65	42 (42.1)			
	>65	56 (57.1)			
ECOG PS^a	0	15 (17.4)	0.181	0.079	0.341
	1	71 (82.6)			
Stage	IA1	4 (4.7)	0.615	0.797	0.170
	IA2	27 (31.4)			
	IA3	34 (39.5)			
	IB	21 (24.4)			
Histology	ADK	53 (61.6)	0.287	0.370	0.065
	SCC	29 (33.7)			
	Large cell carcinoma	3 (3.5)			
	Adenosquamous carcinoma	1 (1.2)			
Type of surgery	Lobectomy/bilobectomy	68 (79)	0.816	0.844	0.440
	Pneumonectomy	2 (2.4)			
	Atypical resection	8 (8.3)			
	Anatomical resection	8 (9.3)			
Smoking history	Current smoker	25 (29.1)	0.308	0.312	0.118
	Former smoker	48 (55.8)			
	Never smoker	13 (15.1)			
Relapse	No	63 (73.3)	-	-	0.745
	Yes	23 (26.7)			
Emphysema	Yes	38 (53.5)	0.086	0.211	0.124
	No	33 (46.5)			
	Unknown	15 (17.4)			
COPD^c	Yes	51 (59.3)	0.838	0.765	0.098
	No	24 (27.9)			
	Unknown	11 (12.8)			
DLCO^d (%)	Mean (Range)	73.4(35-101)	0.270	0.216	0.077
	\geq 60%	50/60 (83.3)			
	<60%	10/60 (11.6)			
Molecular Features	TP53 mutation	17/64 (26.6)	0.358	0.875	0.026
	TP53 WT	47/64 (73.4)			
	KRAS mutation	10/66 (15.2)			
	KRAS WT	56/66 (84.8)			
	EGFR mutation ^b	8/30 (26.7)			
	EGFR WT ^b	22/30 (73.3)			

^a Eastern Cooperative Oncology Group performance status


^b EGFR mutational status was assessed only in adenocarcinoma patients.

^c COPD Chronic Obstructive Pulmonary Disease.


^d DLCO Carbon monoxide diffusing capacity.




Supplementary Figure 2. Kaplan Meier analysis of disease-free survival DFS according to NANCI expression levels 8th TNM edition.



Supplementary Figure 3. Kaplan Meier analysis of disease-free survival DFS according to high/high NANCI/NKX2-1 duplex expression 8th TNM edition.



Supplementary figure 4. Kaplan Meier analysis of overall survival (OS) according to NANCI expression 8th TNM edition.



Supplementary figure 5. Kaplan Meier analysis of overall survival (OS) according to high NANCI/high NKX2-1 duplex expression 8th TNM edition.

Supplementary Table 2. Multivariate analysis for DFS and OS according 8th TNM edition.

<i>Disease free Survival</i>	<i>Hazard Ratio (95%CI)</i>	<i>p-value</i>
Male sex	3.063 (0.876-10.714)	0.080
Emphysema	1.810 (0.850-3.854)	0.124
High NNCI/High NKX2-1	0.488 (0.223-1.067)	0.072
<i>Overall Survival</i>	<i>Hazard Ratio (95%CI)</i>	<i>p-value</i>
Male sex	5.088(0.639-40.499)	0.124
Former/Current smoker	4.208 (0.339-52.158)	0.263
Emphysema	2.143 (0.846-5.425)	0.108
High NNCI/High NKX2-1	0.291 (0.112-0.759)	0.012